Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02654678Phase 2Unknown

Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril

Role: lead

NCT02652741Phase 2Unknown

Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

Role: lead

NCT02652728Phase 2Unknown

Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy

Role: lead

NCT02252692Phase 1Unknown

Relative Bioavailability Study With Enalapril in Healthy Volunteers

Role: lead

All 4 trials loaded